MHRA (Medicines & Healthcare Products Regulatory Agency) updates UK situation after Boston extends recall
This article was originally published in Clinica
Executive Summary
UK healthcare providers are to assess the validity of their stocks of Boston Scientific stent systems according to each product's use-by date, so as to correlate it to the manufacturing date, rather than cross-refer to the extensive list of product codes. So advises the Medicines and Healthcare products Regulatory Agency (MHRA), following the US company's August 5 worldwide update of recalls related to its Taxus paclitaxel-eluting stent and Express2 bare-metal stent systems (see this issue, page 16).
You may also be interested in...
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.